352 results match your criteria Recent Patents on Anti-Cancer Drug Discovery [Journal]


Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.

Recent Pat Anticancer Drug Discov 2019 Feb 12. Epub 2019 Feb 12.

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, NY 11439. United States.

Background: Computational tools are becoming more and more powerful and comprehensive as compared to past decades in facilitating pharmaceutical, pharmacological and clinical practice. Anticancer agents are used either as monotherapy or in combination therapy to treat malignant conditions of the body. A single anti neoplastic agent may be used in different types of malignancies at different doses according to the stage of the disease. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/169933/article
Publisher Site
http://dx.doi.org/10.2174/1574892814666190212164356DOI Listing
February 2019
1 Read

From Antimicrobial to Anticancer Peptides: The Transformation of Peptides.

Recent Pat Anticancer Drug Discov 2019 Jan 19. Epub 2019 Jan 19.

College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou, Hunan Province 425000. China.

Background: Antimicrobial peptides play an important role in the innate immune system. Possessing broad-spectrum antibacterial activity, antimicrobial peptides can quickly treat and kill various targets, including gram-negative bacteria, gram-positive bacteria, fungi, and tumor cells.

Objective: An overview of the state of play with regard to the research trend of antimicrobial peptides in recent years and the situation of targeting tumor cells, and to make statistical analysis of the patents related to anticancer peptides published in recent years, is important both from toxicological and medical tumor therapy point of view. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666190119165157DOI Listing
January 2019
3 Reads

Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.

Recent Pat Anticancer Drug Discov 2019 Jan 16. Epub 2019 Jan 16.

Department of Life Sciences and Systems Biology, University of Torino, Torino. Italy.

Background: Purinergic signalling is involved in several physiological and pathophysiological processes. P2X7 receptor (P2X7R) is a calcium-permeable ion channel that is gaining interest as a potential therapeutic target for the treatment of different diseases including inflammation, pain, psychiatric disorders and cancer. P2X7R is ubiquitously expressed and sensitive to high ATP levels, usually found in tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666190116122256DOI Listing
January 2019
1 Read

Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents.

Recent Pat Anticancer Drug Discov 2019 Jan 15. Epub 2019 Jan 15.

Department of Excellence: Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano. Italy.

Background: Tocotrienols (TTs) are vitamin E derivatives naturally occurring in several plants and vegetable oils. Like Tocopherols (TPs), they comprise four isoforms, α, β, γ and δ, but unlike TPs, they present an unsaturated isoprenoid chain. Recent studies indicate that TTs provide important health benefits, including neuroprotective, anti-inflammatory, anti-oxidant, cholesterol lowering and immunomodulatory effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666190116111827DOI Listing
January 2019
1 Read

New Anti-Cancer Strategies in Testicular Germ Cell Tumors.

Recent Pat Anticancer Drug Discov 2019 Jan 11. Epub 2019 Jan 11.

Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Scuola di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli #39;Federico II', Naples. Italy.

Background: The most common solid malignancy of young men aged 20 to 34 years is testicular germ cell tumor. In addition, the incidence of these tumors has significatively increased throughout the last years. Testicular germ cell tumors are classified into seminoma and nonseminoma germ cell tumors, which take in yolk sac tumor, embryonal cell carcinoma, choriocarcinoma, and teratoma. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/168893/article
Publisher Site
http://dx.doi.org/10.2174/1574892814666190111120023DOI Listing
January 2019
14 Reads

Contemporary Formulations for Drug Delivery of Anticancer Bioactive Compounds.

Recent Pat Anticancer Drug Discov 2019 Jan 10. Epub 2019 Jan 10.

Faculty of Medical Sciences, University "Goce Delcev" Stip, Krste Misirkov No.10-A POB 201, 2000 Stip, R. M. Macedonia, the Former Yugoslav Republic of.

Background: The immense development in the field of anticancer research has led to an increase in the research of bioactive compounds with anticancer potential. It has been known that many bioactive natural compounds have low insolubility (and low bioavailability) as their main drawback when it comes to the formulation and drug delivery to specific sites.

Objective: As many attempts have been made to overcome this issue, this review gives a summary of the current accomplishments regarding the development of new Drug Delivery Systems (DDSs) represented by Nanoparticles (NPs) and exosomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666190111104834DOI Listing
January 2019
5 Reads

Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.

Recent Pat Anticancer Drug Discov 2019 Jan 11. Epub 2019 Jan 11.

Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, P.R. China. Address: No.174 Shazhengjie, Shapingba, Chongqing, P.R.. China.

Background: Chimeric Antigen Receptor (CAR) T cell immunotherapy, as an innovative method for tumor immunotherapy, acquires unprecedented clinical outcomes. Genetic modification not only provides T cells with the antigen-binding function but also endows T cells better immunological functions both in solid and hematological cancer. However, the CAR T cell therapy is not perfect because of several reasons, such as tumor immune microenvironment, and autologous limiting factors of CAR T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666190111120908DOI Listing
January 2019
8 Reads

Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer.

Recent Pat Anticancer Drug Discov 2019 Jan 2. Epub 2019 Jan 2.

Clinical and Molecular Epidemiology, IRCSS San Raffaele Pisana, Via di Valcannuta 247, I-00166 Rome. Italy.

Background: The morbidity and mortality associated with tobacco smoking is well established. Nicotine is the addictive component of tobacco. Nicotine, through non-neuronal 7nicotinic receptor, induces cell proliferation, neo-angiogenesis, epithelial to mesenchymal transition, and inhibits drug-induced apoptosis. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/168708/article
Publisher Site
http://dx.doi.org/10.2174/1574892814666190102122848DOI Listing
January 2019
10 Reads

Lentiviral-Mediated Overexpression of MicroRNA-141 Promotes Cell Proliferation and Inhibits Apoptosis in Human Esophageal Squamous Cell Carcinoma.

Recent Pat Anticancer Drug Discov 2018 12 31. Epub 2018 Dec 31.

Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi’an 710062, Shaanxi, P.R. China.

Background: Esophageal Carcinoma (EC) is the eighth most common cancer worldwide. Numerous studies have highlighted a vital role of microRNAs (miRNAs) in the development of EC. However, the mechanism of microRNA (miRNA)-141 in Esophageal Squamous Cell Carcinoma (ESCC) remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666181231142136DOI Listing
December 2018
1 Read

Death-Associated Protein Kinase 1 As A Promising Drug Target In Cancer and Alzheimer's Disease.

Recent Pat Anticancer Drug Discov 2018 Dec 18. Epub 2018 Dec 18.

Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases Institute for Translational Medicine Fujian Medical University Fuzhou, Fujian 350122. China.

Background: Death-Associated Protein Kinase 1 (DAPK1) plays an important role in apoptosis, tumor suppression and neurodegeneration including Alzheimer's Disease (AD).

Objective: This review will describe the diverse roles of DAPK1 in the development of cancer and AD, and the current status of drug development targeting DAPK1-based therapies.

Methods: Reports of DAPK1 regulation, function and substrates were analyzed using genetic DAPK manipulation and chemical DAPK modulators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892814666181218170257DOI Listing
December 2018
14 Reads

Commentary: High-throughput Strategy Accelerates the Progress of Marine Anticancer Peptide Drug Development.

Recent Pat Anticancer Drug Discov 2018 11 14. Epub 2018 Nov 14.

Cancer Centre, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau, P.R.. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813999181114152127DOI Listing
November 2018
1 Read

Cucurbitacins as Anticancer Agents: A Patent Review.

Recent Pat Anticancer Drug Discov 2018 Nov 19. Epub 2018 Nov 19.

Department of Plant Sciences, Quaid-i-Azam University, Islamabad. Pakistan.

Background: Cucurbitacins belong to a group of tetracyclic triterpenoids that display a wide range of biological effects. In the past, numerous cucurbitacins have been isolated from natural sources and many active compounds have been synthesized using the privileged scaffold in order to enhance its anticancer effects.

Objective: This review covers patents on the therapeutic effects of natural cucurbitacins and their synthetic analogs published during the past decade. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/167481/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666181119123035DOI Listing
November 2018
13 Reads

Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.

Recent Pat Anticancer Drug Discov 2018 Oct 31. Epub 2018 Oct 31.

Benemerita Universidad Autonoma de Puebla - Centro Universitario de Vinculacion y Transferencia de Tecnologia Puebla, Puebla. Mexico.

Background: Cancer is one of the leading causes of death in the world and it is necessary to develop new strategies for its treatment because most therapies have limited access to many types of tumors, as well as low therapeutic efficacy and high toxicity.

Objective: The present review aims to provide to identify recent patents of drug delivery nanostructured systems that may have application in improving cancer treatment.

Method: Recent patents regarding the drug delivery nanostructured systems for cancer treatment were obtained from the patent databases of the six main patent offices of the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Intellectual Property Office of China and Korean Intellectual Property Office. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666181031154146DOI Listing
October 2018
1 Read

Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A review update of Patent Literature.

Recent Pat Anticancer Drug Discov 2018 Oct 29. Epub 2018 Oct 29.

College of Biomedical and Health Sciences, Konkuk University, Chungju 27478. Korea.

Background: In the last few decades, cancer immunotherapy has been extensively researched, and novel checkpoint signaling mechanisms involving programmed death (PD)-1 and PD-ligand 1 (PD-L1) receptors have been targeted. The PD-1/PD-L1 binding and interaction play a critical role in the development of malignancies.

Objective: The present review focuses on recent patents on the pharmacological and biological cancer-regulating properties of PD-1/PD-L1 inhibitors involved in immunotherapeutic cancer drug development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666181029142812DOI Listing
October 2018
24 Reads

Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments.

Recent Pat Anticancer Drug Discov 2018 ;13(4):455-468

The Hepatosplenic Surgery Center, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin 150001, China.

Background: Solid tumors often contain hypoxic microenvironments due to abnormal vasculatures and outweighing demands of oxygen. Cancer cells rely on anaerobic respiration, leading to sequential acidic microenvironments. Hypoxic and acidic microenvironments cause genetic instability and activate signaling pathways, contributing to cancer progression and therapy resistance, and have become targets for developing novel anti-cancer agents. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/165023/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180831102519DOI Listing
December 2018
17 Reads

Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review.

Recent Pat Anticancer Drug Discov 2018 ;13(4):411-421

Department of Botany, GPGC Parachinar Kurram Agency, Pakistan.

Withanolides are C-28 ergostane steroids known to demonstrate some very interesting therapeutic properties. Numerous withanolides have been isolated from a variety of different plant species and can be employed to treat various types of cancers. Withanolides are indeed capable of demonstrating excellent anticancer, anti-inflammatory, and neuroprotective activities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180808154928DOI Listing
December 2018
18 Reads

Semi-Synthetic Derivatives of Heliomycin with an Antiproliferative Potency.

Recent Pat Anticancer Drug Discov 2018 Oct;13(4):469-472

Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russian Federation.

Background: Heliomycin (resistomycin), an antibiotic with broad spectra of biological activities including antimicrobial, antifungal, antiviral, and antiproliferative. However, an extremely low solubility in aqueous media and in the majority of organic solvents limits its practical application.

Objective: Due to a high practical potential of heliomycin, new routes of structural modification are strongly required to improve its solubility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180723150542DOI Listing
October 2018
1 Read

Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.

Authors:
Zsuzsanna Suba

Recent Pat Anticancer Drug Discov 2018 ;13(4):428-444

National Institute of Oncology, Department of Molecular Pathology, Address: H-1122, Ráth György str. 7-9, Budapest, Hungary.

Background: The pharmaceutical development of endocrine disruptors could not achieve appropriate advances in the field of anticancer fight.

Objective: Considerations on the principles of currently used endocrine therapies.

Methods: Comparison of the results of genetic studies being performed on breast cancer cells treated with estrogens, synthetic estrogens and antiestrogens. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/163948/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180720123732DOI Listing
December 2018
2 Reads

CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1.

Recent Pat Anticancer Drug Discov 2018 ;13(3):360-367

Department of Pharmacology, Capital Medical University, Beijing 100069, China.

Background: CS5931, a novel marine peptide, was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. However, its molecular targets have not been elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180628170240DOI Listing
November 2018
6 Reads

Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature.

Recent Pat Anticancer Drug Discov 2018 ;13(4):422-427

Department of Life Sciences and Systems Biology, University of Torino, Torino, Italy. Address: via Accademia Albertina 13, Torino, Italy.

Background: Massive vessel recruitment is required to sustain rapid tumor growth by delivering oxygen and nutrients. Current strategies to counteract angiogenesis are mostly aimed at reducing tumor vessel density. However, many of these drugs have been shown to trigger hypoxia, thus exacerbating tumor aggressiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180528105023DOI Listing
December 2018
1 Read

Synthesis, In Silico and In Vitro Cytostatic Activity of New Lipophilic Derivatives of Hydroxyurea.

Recent Pat Anticancer Drug Discov 2018 ;13(3):378-385

Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Background: Hydroxyurea (HU) is used to treat cancer. HU has a short half-life due to its small molecular weight and high polarity, therefore a high dosage of the drug should be used which introduces side effects and more rapid development of resistance.

Objective: The objective of the current study is to design new lipophilic analogues of hydroxyurea with higher stability and better cell penetration. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/162243/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180517102255DOI Listing
November 2018
24 Reads

Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.

Recent Pat Anticancer Drug Discov 2018 ;13(3):308-340

Rothschild Hospital - Geriatric Department, Assistance Publique Hôpitaux de Paris, Paris, France.

Objective: Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies with a poor outcome. The discovery of new molecular biomarkers has led to the emergence of new drugs in recent years that target various signaling pathways.

Methods: We examined all pertinent published patents through 2015 that analyzed novel methods for the diagnosis and treatment of T cell lymphoma, as well as related published and unpublished studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180517102801DOI Listing
November 2018
2 Reads

Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature.

Recent Pat Anticancer Drug Discov 2018 ;13(3):348-359

Oficina de Comercializacion de Tecnologia, Centro Universitario de Vinculacion y Transferencia de Tecnologia, Benemerita Universidad Autonoma de Puebla, Puebla CP 72570, Mexico.

Background: Despite dramatic advances in cancer treatment that lead to long-term survival, there is an increasing number of patients presenting with clinical manifestations of cerebral metastasis in breast cancer, for whom only palliative treatment options exist.

Objective: The present review based on researches aims to provide identification of recent patens of breast cancer brain metastasis that may have application in improving cancer treatment.

Methods: Recent patents regarding the breast cancer brain metastasis were obtained from USPTO patent databases, Esp@cenet, Patentscope and Patent Inspiration®. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180430113605DOI Listing
November 2018
4 Reads

Recent Progress of Marine Polypeptides as Anticancer Agents.

Recent Pat Anticancer Drug Discov 2018 ;13(4):445-454

Departments of Chemistry and Chemical Biology, Chemical and Biological Engineering, Biology and Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, United States.

Background: Marine environment constitutes an almost infinite resource for novel anticancer drug discovery. The biodiversity of marine organisms provides a rich source for the discovery and development of novel anticancer peptides in the treatment of human cancer. Marine peptides represent a new opportunity to obtain lead compounds in biomedical field, particularly for cancer therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180430110033DOI Listing
December 2018
12 Reads

Low Dose of Acacetin Promotes Breast Cancer MCF-7 Cells Proliferation Through the Activation of ERK/ PI3K /AKT and Cyclin Signaling Pathway.

Recent Pat Anticancer Drug Discov 2018 ;13(3):368-377

Key Laboratory of Xinjiang Endemic Phytomedicine Resources of Ministry of Education, School of Pharmacy, Shihezi University, Shihezi 832002, Xinjiang, China.

Background: Phytoestrogens have been proposed as replaceable medicines for climacteric hormone replacement therapy, on the basis of EP3138562 and US5516528. However, recent studies demonstrated that phytoestrogens might promote the proliferation of breast cancer cells, which is rooted in their estrogenic activity. Acacetin, as one phytoestrogen, has been reported to exhibit estrogenic activity. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/161459/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180420154012DOI Listing
November 2018
3 Reads

Anti-Cancer Effect of α-Solanine by Down-Regulating S100P Expression in Colorectal Cancer Cells.

Recent Pat Anticancer Drug Discov 2018 ;13(2):240-247

Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Background: α-Solanine, the most important and active component of Solanum nigrum, was found to have anti-cancer activity on multiple cancer cells. However, its effects on colorectal cancer (CRC) and associated molecular mechanisms remain to be further elucidated.

Objective: In this study, we investigated the anti-cancer effects of α-solanine against CRC cells in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180329163945DOI Listing
October 2018
5 Reads

TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients.

Recent Pat Anticancer Drug Discov 2018 ;13(3):341-347

Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Raoping Rd, Shantou 515041, Guangdong, China.

Background: Paclitaxel (PTX) has remarkable anti-tumor activity, but it causes severe toxicities. There is an urgent need to seek an appropriate pharmacokinetic parameter of PTX to improve treatment efficacy and reduce adverse effects.

Objective: To evaluate the association of pharmacokinetic parameter TC > 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180305170439DOI Listing
November 2018
18 Reads

PARP Inhibitors in Ovarian Cancer.

Recent Pat Anticancer Drug Discov 2018 ;13(4):392-410

Department of Oncology, University of Torino, Torino, Italy.

Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.

Objectives: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180305165256DOI Listing
December 2018
8 Reads

Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.

Recent Pat Anticancer Drug Discov 2018 ;13(3):302-307

Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Background: Tamoxifen is widely administered for patients with estrogen receptor-positive breast cancer. Despite many patients benefiting from Tamoxifen as an effective anti-hormonal agent in adjuvant therapy, a noticeable number of patients tend to develop resistance.

Objective: The aim of this study was to shed light upon the molecular mechanisms associated with Tamoxifen resistance which can help improve current treatment strategies available for stimulating responsiveness and combating resistance. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/160233/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180305164634DOI Listing
November 2018
17 Reads

The Application of lncRNAs in Cancer Treatment and Diagnosis.

Recent Pat Anticancer Drug Discov 2018 ;13(3):292-301

Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.

Background: It is increasingly evident that lncRNAs have various biological functions playing as essential regulators, getting involved in diverse cellular processes. Many of the lncRNAs show aberrant expression in cancer, which is associated with different cancer types. The dysregulation of lncRNAs has been increasingly linked to cancer carcinogenesis and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180226121819DOI Listing
November 2018
4 Reads

Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation.

Recent Pat Anticancer Drug Discov 2018 ;13(3):272-291

Department of Oral Pathology, Manipal College of Dental Sciences, Manipal University, Manipal - 576104, India.

Background: Oral submucous fibrosis is an oral potentially malignant disorder with high incidence of malignant transformation and rising global prevalence. However, the genesis of oral submucous fibrosis is still unclear despite superfluity of literature. In the background of ineffective treatment, it is necessary to decode its onset and progression before designing customized treatment regimens. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/160134/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180227103147DOI Listing
November 2018
25 Reads

Synthesis and DFT Study on Hantzsch Reaction to Produce Asymmetrical Compounds of 1,4-Dihydropyridine Derivatives for P-Glycoprotein Inhibition as Anticancer Agent.

Recent Pat Anticancer Drug Discov 2018 ;13(2):255-264

Chemical Injuries Research Center, System Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Background: P-glycoprotein (P-gp) causes the efflux of cancer chemotherapy drugs from tumor cells, so its inhibition can be one target for designing and synthesis of new anticancer drugs.

Objective: In this study, new compounds of 1,4-dihydropyridine (DHP) were recommended as inhibitors of P-gp.

Methods: We synthesized new symmetrical DHP with 36% - 43% yield by the reaction of new reactants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180220112613DOI Listing
October 2018
31 Reads

Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation.

Recent Pat Anticancer Drug Discov 2018 ;13(2):133-144

Group for Molecular Oncology, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, 11129 Belgrade, Serbia.

Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/159948/article
Publisher Site
http://dx.doi.org/10.2174/1574892813666180220105958DOI Listing
October 2018
11 Reads

Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.

Recent Pat Anticancer Drug Discov 2018 ;13(2):201-208

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi, 10, I-56126, Pisa, Italy.

Background And Objective: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR1-VEGFR3), fibroblast growth factor receptors (FGFR1-FGFR4), Platelet-Derived Growth Factor Receptor (PDGFR)α, rearranged during transfection (RET), and v-kit (KIT) signaling networks implicated in tumor angiogenesis.

Method: Here, we review the scientific literature about lenvatinib in the treatment of thyroid cancer.

Results: In vitro studies have shown antineoplastic activity of lenvatinib in Differentiated Thyroid Cancer (DTC), mainly because of its antiangiogenetic effects, but a slight effect on thyroid cancer cell proliferation has been shown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180220110729DOI Listing
October 2018
10 Reads

Anti-Oxidants as Chemopreventive Agents in Prostate Cancer: A Gap Between Preclinical and Clinical Studies.

Recent Pat Anticancer Drug Discov 2018 ;13(2):224-239

Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Background: Tumor cells may be expressed as a result of oxidative stress. The extent of oxidative stress correlates with the aggressive and metastatic potency of cancer.

Objective: One simple way to control prostate cancer is through chemoprevention which refers to the administration of natural or synthetic agents to block, reverse, or delay the process of carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180213164700DOI Listing
October 2018
2 Reads
4.295 Impact Factor

Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.

Recent Pat Anticancer Drug Discov 2018 ;13(2):209-223

Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, GR26504 Patras, Greece.

Background: Glioblastoma (GBM) is the most aggressive and common brain tumor in adults, currently lacking effective life-prolonging and recurrence-preventing therapy; median survival of GBM patients stands at only 14-16 months. Increasing lines of evidence indicate that Anaplastic lymphoma kinase (ALK), a druggable tyrosine kinase receptor over-expressed in GBM, represents a potential therapeutic target in this tumor.

Objective: An overview of the state of the art and the existing recent patents regarding potential exploitation of ALK as a therapeutic target and/or diagnostic/prognostic factor in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666180115151554DOI Listing
October 2018
5 Reads

Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells.

Recent Pat Anticancer Drug Discov 2018 ;13(2):248-254

Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, Henan 453003, China.

Background: Vincristine (VCR) resistance can lead to cancer chemotherapy failure. Although changes in gene expression are responsible for drug resistance, the specific identities and roles of these genes remain unclear.

Objective: In this study, we aimed to identify differentially expressed genes and mechanisms of VCR resistance in colorectal cancer (CRC) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666171221120504DOI Listing
October 2018
9 Reads

Advances in the Discovery of Anthraquinone-Based Anticancer Agents.

Recent Pat Anticancer Drug Discov 2018 ;13(2):159-183

Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russian Federation.

Background: The anthracene-9,10-dione (anthraquinone) derivatives represent an exceptionally valuable class in anticancer drug development. An outstanding antitumor potency of the anthracycline antibiotics attracted the attention of medicinal chemists since the discovery of these chemotypes. The prominent anthraquinone-based drugs doxorubicin, mitoxantrone as well as more recent epirubicin, idarubicin, and valrubicin are successfully used in chemotherapy of hematological malignancies and solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666171206123114DOI Listing
October 2018
7 Reads

PARP Inhibitors in Epithelial Ovarian Cancer.

Recent Pat Anticancer Drug Discov 2018 ;13(2):145-158

Rebecca and John Moores Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, United States.

Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage disease remain limited, reflecting the need for novel therapies. Poly(ADP-ribose) polymerase (PARP) inhibitors have recently demonstrated a significant therapeutic effect in patients with recurrent, high grade serous ovarian cancer, both in the treatment of existing disease and in prolonging the disease-free interval. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892813666171204094822DOI Listing
October 2018
5 Reads

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.

Recent Pat Anticancer Drug Discov 2018 ;13(2):184-200

Experimental Pharmacology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale - IRCCS, 80131 Naples, Italy.

Background: Modifications of lipid metabolism have been progressively accepted as a hallmark of tumor cells and in particular, an elevated lipogenesis has been described in various types of cancers.

Objective: Important or deregulated activity of the mevalonate pathway has been demonstrated in different tumors and a wide range of studies have suggested that tumor cells are more dependent on the unceasing availability of mevalonate pathway metabolites than their non-malignant complements.

Methods: This study provides an overview of the state of the art of statins treatment on human cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666171129141211DOI Listing
October 2018
7 Reads

Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches.

Recent Pat Anticancer Drug Discov 2018 ;13(1):70-85

Drug Discovery Lab, Dept. of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)- Ahmedabad, Gujarat. India.

Background: Cancer is one of the leading causes of morbidity and mortality worldwide. Brain cancer is identified as one of the most formidable forms of cancer due to several hurdles posed by the anatomy and physiology of the brain on the therapeutic strategies employed for treating brain cancer. Poor prognosis and high relapse rate further aggravate the situation leading to the high mortality rate in brain cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666171129142023DOI Listing
August 2018
37 Reads

Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature.

Recent Pat Anticancer Drug Discov 2018 ;13(1):40-69

Department of Drug Sciences, Laboratory of Pharmacology, Faculty of Pharmacy, University of Porto, Porto. Portugal.

Background: Adenosine is a purine, with an adenine group and a ribose sugar, formed endogenously by ATP catabolism both intracellularly and extracellularly. Among the medicinal features of adenosine and its receptors (A1, A2A, A2B and A3), anticancer activity has been an intense field of research. The anticancer potential of adenosine receptor ligands has been brought to the forefront of research and evidenced in innumerous research articles and patents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666171108115959DOI Listing
August 2018
40 Reads

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.

Recent Pat Anticancer Drug Discov 2018 ;13(1):86-105

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy.

Background: Human dihydroorotate dehydrogenase (hDHODH, EC 1.3.5. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/156928/article
Publisher Site
http://dx.doi.org/10.2174/1574892812666171108124218DOI Listing
August 2018
15 Reads

The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer.

Recent Pat Anticancer Drug Discov 2018 ;13(1):118-124

Department of Pathology, University of Medicine and Pharmacy, Tirgu-Mures. Romania.

Background: Metastases to the stomach are extremely rare and the metastatic pathway is not well understood.

Objective: To present two unusual gastric metastases and a review of the literature regarding the pathway of Epithelial Mesenchymal Transition (EMT) in the metastatic cells.

Method: The clinicopathological aspects of the two cases were presented in the light of the most recent patents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/2212798409666171101121108DOI Listing
August 2018
8 Reads

Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.

Recent Pat Anticancer Drug Discov 2018 ;13(1):2-17

Institute of Translational Pharmacology (IFT), Department of Biomedical Sciences, National Research Council (CNR), via Fosso del Cavaliere 100 - 00133 Rome. Italy.

Background: Nucleic acid sensing is an essential strategy employed by the innate immune system to detect both pathogen-derived nucleic acids and self-DNA released by host apoptotic or necrotic cells. The presence of nucleic acids that gain access to the cytoplasm is perceived by mammalian cells as "stranger" or "danger" signals that trigger a myriad of immunological responses. Recent publications have highlighted the importance of nucleic acid sensing machinery as mediator of innate and adaptive immunity, and cGAS, STING and RIG-I agonists have been validated as immunooncology agents in cancer therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666171030163804DOI Listing
August 2018
4 Reads

NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents.

Recent Pat Anticancer Drug Discov 2018 ;13(1):106-117

College of Biomedical and Health Sciences, Konkuk University, Chungju. Korea.

Background: Inflammasomes are recognized as key regulators in innate immunity from the pathogenic to endogenous danger signals. Although controlled activation of inflammasome is highly beneficial, dysregulation of inflammasome activation plays central role in various autoimmune, inflammatory disorders and aid in promoting various forms of cancers in humans such as breast cancer, fibrosarcoma, gastric carcinoma, and lung metastasis. NLRP3 inflammasome activation has been emerged as a topic of interest and is under profound investigation for its involvement in multiple forms of cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666171027102627DOI Listing
August 2018
16 Reads

Strategies to Tackle Radiation Resistance by Penetrating Cancer Stem Cell Line of Scrimmage.

Recent Pat Anticancer Drug Discov 2018 ;13(1):18-39

School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005. Korea.

Background: Radiation therapy has become a common therapy for cancer patients and largely improved therapeutic outcomes. However, recurrence after radiation therapy is still a major unsolved concern of cancer patients. The Cancer Stem Cells (CSCs), a small sub-population with the capacity of self-renewal and differentiation into diverse types of cancer cells, are considered as strong drivers of metastasis, resistance, and recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666171003150410DOI Listing
August 2018
9 Reads

Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.

Recent Pat Anticancer Drug Discov 2017 Nov;12(4):384-400

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia.

Background: Protoberberine isoquinoline alkaloids are found in many plant species. They consist of a diverse class of secondary metabolites with many pharmacologically active members, such as different derivatives of berberine already patented. In the development of approximately 20-25% of all cancers, altered hedgehog (Hh) signalling is involved where the smoothened (Smo) transmembrane receptor triggers Hh signalling pathway towards Gli1 gene expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666170929131247DOI Listing
November 2017
52 Reads

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.

Authors:
Romeo G Mihaila

Recent Pat Anticancer Drug Discov 2017 Nov;12(4):283-295

"Lucian Blaga" University of Sibiu, Faculty of Medicine, Spitalul Clinic Judetean de Urgenta Sibiu, str Lucian Blaga, nr 2A, Sibiu, 550169 Sibiu, Romania.

Background: Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas.

Objective: Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666170920110054DOI Listing
November 2017
27 Reads

Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment.

Recent Pat Anticancer Drug Discov 2017 Nov;12(4):323-339

Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.

Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.

Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574892812666170829150057DOI Listing
November 2017
12 Reads